Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol 2002;12:111–27.
   PubMed Web of Science ®Google Scholar
• Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603–9.
   PubMed Web of Science ®Google Scholar
• Hosokawa O, Miyanaga T, Kaizaki Y, Hattori M, Dohden K, Ohta K, Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol 2008;43:1112–15.
   PubMed Web of Science ®Google Scholar
• Samloff IM. Immunologic studies of human group I pepsinogens. J Immunol 1971;106:962–8.
   PubMed Web of Science ®Google Scholar
• Samloff IM. Pepsinogens, pepsins, and pepsin inhibitors. Gastroenterology 1971;60:586–604.
   PubMed Web of Science ®Google Scholar
• Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987;22:133–41.
   PubMedGoogle Scholar
• Miki K, Ichinose M, Ishikawa KB, Yahagi N, Matsushima M, Kakei N, Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993;84:1086–90.
   PubMedGoogle Scholar
• Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–40.
   PubMed Web of Science ®Google Scholar
• Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735–9.
   PubMed Web of Science ®Google Scholar
• Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007;8:8–14.
   PubMed Web of Science ®Google Scholar
• Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, The serum pepsinogen test as a predictor of gastric cancer: the Hisayama Study. Am J Epidemiol 2006;163:629–37.
   PubMed Web of Science ®Google Scholar
• Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138–43.
   PubMed Web of Science ®Google Scholar
• Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev 2008;17:838–45.
   PubMed Web of Science ®Google Scholar
• Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764–8.
   PubMed Web of Science ®Google Scholar
• Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. Diabetologia 1993;36:1198–203.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kiyohara Y, Kato I, Matsumoto T, Yamagata H, Kubo M, Incidence and prognosis of gastric cancer in a population based cohort survey: the Hisayama Study. Scand J Gastroenterol 2004;39:459–63.
   PubMed Web of Science ®Google Scholar
• Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama Study. Arch Intern Med 2000;160:1962–8.
   PubMedGoogle Scholar
• SAS/STAT user's guide, version 8. Cary, NC: SAS Institute, Inc. 1999.
   Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–5.
   PubMed Web of Science ®Google Scholar
• Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670–5.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
   PubMed Web of Science ®Google Scholar
• Miki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer. Adv Exp Med Biol 1995;362:139–43.
   PubMedGoogle Scholar
• Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999;44:693–7.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res 1995;86:1210–15.
   PubMedGoogle Scholar
• Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141–7.
   PubMed Web of Science ®Google Scholar
• Shikata K, Doi Y, Yonemoto K, Arima H, Ninomiya T, Kubo M, Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study. Am J Epidemiol 2008;168:1409–15.
   PubMed Web of Science ®Google Scholar
• Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007;10:75–83.
   PubMed Web of Science ®Google Scholar
• Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994;54:1941s–3s.
   Web of Science ®Google Scholar
• Kokkola A, Kosunen TU, Puolakkainen P, Sipponen P, Harkonen M, Laxen F, Spontaneous disappearance of Helicobacter pylori antibodies in patients with advanced atrophic corpus gastritis. APMIS 2003;111:619–24.
   PubMed Web of Science ®Google Scholar
• Lambet R, Guilloux A, Oshima A, Pompe-kirn B, Bray F, Parkin M, Incidence and mortality from stomach cancer in Japan, Slovenia, and the USA. Int J Cancer 2002;97:811–18.
   PubMed Web of Science ®Google Scholar
• Hisamichi S. Screening for gastric cancer. World J Surg 1989;13:31–7.
   PubMed Web of Science ®Google Scholar